This invention discloses a uniform, ultrafine
polymer nanomicelle, its preparation method, and its applications. The
polymer nanomicelle is first formed by modifying a material based on poly(lactic-co-liquid) with ligands containing double bonds to create a
polymer containing
unsaturated bonds. The polymer then encapsulates
berberine (BBR) via a self-emulsification process, followed by UV cross-linking and pH adjustment. The polymer nanomicelle uses materials obtained from FDA-approved
excipient PLGA through simple modification, and subsequently,
drug-loaded nanomicelles with a particle size of less than 10 nm are prepared via self-emulsification. Due to their
small particle size, the nanomicelles can be transported through the intercellular spaces of epithelial cells, effectively improving
drug bioavailability.
Combined use with the intestinal permeabilizer SNAC can further enhance the transintestinal
absorption capacity of the nanoparticles. The polymer nanomicelles exhibit high uniformity, good stability, good safety and
biocompatibility, and no toxic side effects, making them a promising candidate for treating type 2 diabetes.